



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/027,433	12/21/2001	Delwin Jackson	5393	1883

7590 12/23/2002

Milliken & Company  
P.O. Box 1927  
Spartanburg, SC 29304

EXAMINER
----------

BARR, MICHAEL E

ART UNIT	PAPER NUMBER
----------	--------------

1762

DATE MAILED: 12/23/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.

10/027,433

Applicant(s)

JACKSON ET AL

Examiner

Michael Barr

Art Unit

1762

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-17 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-17 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 4.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_

## DETAILED ACTION

### *Claim Rejections - 35 USC § 112*

1. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

2. Claims 1-17 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1 cites the limitation of "a modified plate contact method". This limitation is indefinite as it is not clearly defined as to what is encompassed by the "modified plate contact method". The specification does not clear define such a method.

### *Claim Rejections - 35 USC § 102*

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in-

(1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effect under this subsection of a national application published under section 122(b) only if the international application designating the United States was published under Article 21(2)(a) of such treaty in the English language; or

(2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that a patent shall not be deemed filed in the United States for the purposes of this subsection based on the filing of an international application filed under the treaty defined in section 351(a).

4. Claims 1-16 are rejected under 35 U.S.C. 102(e) as being anticipated by Bellantone et al.

Art Unit: 1762

Bellantone et al. teaches applying an antimicrobial agent to a substrate by providing a substrate, providing a sol-gel precursor formulation comprising a host precursor component (TEOS, TMOS) and an antimicrobial agent (silver oxide), allowing the formulation to form a sol-gel (which reads on the claimed compounding step), applying the sol-gel to the substrate and heating to temperatures below 800 °C to form a finished coating on the substrate (Col. 4, line 30-Col. 5, line 50; Col. 7, lines 1-6). Bellantone et al. does not teach the log kill rate for *Klebsiella pneumoniae*. However, since Bellantone et al. teaches the claimed method and materials used, it would have been expected that the finished substrate would have inherently had the claimed log kill rate for *Klebsiella pneumoniae*. If this is not the case, then it must be due to critical limitations not being claimed. Furthermore, the mere observation of another benefit from an otherwise old process does not form the basis for patentability (*Allen et al. vs. Coe* 57 USPQ 136).

### ***Claim Rejections - 35 USC § 103***

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

6. Claims 1-17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Oku et al. in view of WO 91/08179 by Deith ("Deith").

Oku et al. teaches applying an antimicrobial agent to a substrate by providing a ceramic substrate, providing a conventional silica-based glaze containing an antimicrobial agent (silver

Art Unit: 1762

oxide, silver-containing ion exchange compound), applying the glaze to the substrate and heating to form a finished coating on the substrate (Col. 1, line 50-Col. 2, line 18; Col. 3, lines 3-32; Example 1). Oku et al. does not teach applying the microbial agent with a sol-gel. Deith teaches applying a silica-based glaze to a ceramic substrate by a sol-gel method, as an alternative to a conventional, high temperature firing glaze, where the glaze is formed providing a sol-gel precursor formulation comprising a host precursor component (TEOS), allowing the formulation to form a sol-gel (which reads on the claimed compounding step), applying the sol-gel to the substrate and heating to temperatures below 800 °C to form a finished coating on the substrate (Pg. 3, lines 12-34; Example). It would have been an obvious modification for one skilled in the art to apply the glaze of Oku et al. by the sol-gel method of Deith, where antimicrobial agent is merely added to the sol-gel glaze composition, with the expectation of gaining the additional benefit of providing the desired ceramic glaze layer in Oku et al. at lower heat treating temperatures than with the conventional glaze of Oku et al., as is taught by Deith.

Oku et al. and Deith do not teach the log kill rate for *Klebsiella pneumoniae*. However, since Oku et al. and Deith teach the claimed method and materials used, it would have been expected that the finished substrate would have inherently had the claimed log kill rate for *Klebsiella pneumoniae*. If this is not the case, then it must be due to critical limitations not being claimed. Furthermore, the mere observation of another benefit from an otherwise old process does not form the basis for patentability (*Allen et al. vs. Coe* 57 USPQ 136).

Art Unit: 1762


*Conclusion*

7. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Konagaya et al. teaches silver as an antimicrobial material.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Barr whose telephone number is 703-305-7919. The examiner can normally be reached on Monday-Thursday 6:00 am-4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shrive Beck can be reached on 703-308-2333. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9310 or 703-305-5408 for regular communications and 703-872-9311 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0661.

A handwritten signature in black ink, appearing to read 'MB', with a large, sweeping horizontal stroke underneath it.

Michael Barr  
Primary Examiner  
Art Unit 1762

MB  
December 9, 2002